Literature DB >> 7332729

Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy.

M Frisk-Holmberg, L Paalzow, P O Edlund.   

Abstract

1 Clonidine kinetics were studied in 21 patients with essential hypertension. All received two bolus i.v. injections in the mean dose range of (0.78--3.36 micrograms kg-1) and one single oral dose (mean dose 1.7--2.3 micrograms kg-1) on separate occasions. The kinetics were also studied in some of these patients after multiple therapeutic oral dose (mean dose 1.1 or 1.9 micrograms kg-1) twice daily during a dosage interval after 6--12 months monotherapy with clonidine. The multiple oral dosage was based on the therapeutic response. 2 With increasing i.v. doses the rate constants (alpha, beta) decreased and the plasma clearance was reduced by 74% (9.94--2.61 ml min-1 kg-1) indicating dose-dependent kinetics. The volume of distribution (Vd beta) did not change with dose in contrast to the volume of the plasma compartment (Vc) which was increased at the highest doses. 3 The single oral dose kinetics agreed with the i.v. kinetics at comparable dose. The bioavailability was 90%. 4 During multiple oral dosing the elimination rate constants decreased compared to the single dose. The plasma clearance increased (7.18 ml min-1 kg-1) compared to the corresponding single dose (4.17 ml min-1 kg-1). The latter change was probably caused by the decrease in bioavailability to about 65%. 5 The pharmacodynamic properties of the drug could explain the changes in pharmacokinetics with increased dose and during multiple doses.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332729      PMCID: PMC1401969          DOI: 10.1111/j.1365-2125.1981.tb01284.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

2.  Structure activity relationships for central and peripheral alpha adrenergic activities of imidazoline derivatives.

Authors:  H S Boudier; J de Boer; G Smeets; E J Lien; J van Rossum
Journal:  Life Sci       Date:  1975-08-01       Impact factor: 5.037

3.  [Studies on the pharmacokinetics and on the metabolism of 2(2,6-dichlorphenylamino)-2-imidazoline-hydrochloride (St 155)].

Authors:  D Rehbinder; W Deckers
Journal:  Arzneimittelforschung       Date:  1969-02

4.  Determination of clonidine in human plasma by glass capillary gas chromatography with electron-capture detection.

Authors:  P O Edlund
Journal:  J Chromatogr       Date:  1980-01-04

5.  Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension.

Authors:  L M Wing; J L Reid; D S Davies; E A Neill; P Tippett; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1977-12-28       Impact factor: 2.953

6.  [Metabolic degradation of clonidine (author's transl)].

Authors:  S Darda; H J Förster; H Sthle
Journal:  Arzneimittelforschung       Date:  1978

7.  Pharmacokinetics of clonidine in the rat and cat.

Authors:  L K Paalzow; P O Edlund
Journal:  J Pharmacokinet Biopharm       Date:  1979-10

8.  Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients.

Authors:  M Frisk-Holmberg; P O Edlund; L Paalzow
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

9.  Clonidine delays small intestinal transit in the rat.

Authors:  M J Ruwart; M S Klepper; B D Rush
Journal:  J Pharmacol Exp Ther       Date:  1980-03       Impact factor: 4.030

  9 in total
  10 in total

Review 1.  Is clonidine an effective smoking cessation therapy?

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

2.  New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man.

Authors:  D Arndts; J Doevendans; R Kirsten; B Heintz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Substrate specificity and mechanism of the intestinal clonidine uptake by Caco-2 cells.

Authors:  Wiebke Fischer; Linda Metzner; Kathrin Hoffmann; Reinhard H H Neubert; Matthias Brandsch
Journal:  Pharm Res       Date:  2006-12-13       Impact factor: 4.200

4.  Population pharmacokinetics of intravenous clonidine for sedation during paediatric extracorporeal membrane oxygenation and continuous venovenous hemofiltration.

Authors:  Niina Kleiber; Ron A A Mathôt; Maurice J Ahsman; Enno D Wildschut; Dick Tibboel; Saskia N de Wildt
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

5.  A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Nina Isoherranen; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2013-01-25       Impact factor: 3.922

Review 6.  Effect of pregnancy on the pharmacokinetics of antihypertensive drugs.

Authors:  Gail D Anderson; Darcy B Carr
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Relationship between the cardiovascular effects and steady-state kinetics of clonidine in hypertension. Demonstration of a therapeutic window in man.

Authors:  M Frisk-Holmberg; L Paalzow; L Wibell
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

Review 9.  Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Authors:  Henry A Spiller; Hannah L Hays; Alfred Aleguas
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 10.  Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments.

Authors:  Fei Tang; Chee M Ng; Henrietta S Bada; Markos Leggas
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.